IMMUTEP Ltd IMMP
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
IMMUTEP Ltd (IMMP) is a healthcare company listed in the US with a market value of about $26M. In fiscal year 2025 it had revenue of $7M and net income of -$40M, a net margin of -594.6%.
Its overall Stock Analiz score is 1.6 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of -10% a year.
About IMMUTEP
IMMUTEP is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $2M in 2016 to $7M in 2025, growth of about 18.1% a year. It was profitable in 0 of the last 10 years in our data.
Score: 1.6 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $7M | $5M | $3M | $5M | $3M | $11M | $5M | $5M | $3M | $2M |
| Net income | -$40M | -$28M | -$26M | -$22M | -$22M | -$9M | -$13M | -$9M | -$7M | -$46M |
| Free cash flow | -$41M | -$23M | -$23M | -$21M | -$13M | -$7M | -$11M | -$6M | -$7M | -$8M |
| EPS (diluted) | $-5.44 | $-3.86 | $-3.59 | $-3.01 | $-3.04 | $-1.25 | $-1.74 | $-1.28 | $-0.98 | $-6.26 |
| Net margin | -594.6% | -544.9% | -767.2% | -476.6% | -753.6% | -81.6% | -244.9% | -173.3% | -221.9% | -3056.6% |
| ROIC | — | — | — | — | — | — | — | — | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does IMMUTEP pay a dividend?
Not currently.
Is IMMUTEP a good stock to buy?
We do not give buy or sell advice. IMMUTEP scores 1.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.